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Abstract 
Background. HCV infection is associated with musculoskeletal manifestations such as 
chronic widespread pain, sicca syndrome, polyarthritis, and a reduced HRQOL. Little 
data is available on the effect of treatment on these manifestations. This study 
measured changes in extrahepatic symptoms and HRQOL before and after antiviral 
treatment in a large UK patient cohort. Methods. 118 patients completed HQLQ and 
rheumatological questionnaires before and after treatment with pegylated interferon-α 
and ribavirin, with specific regard to chronic widespread pain, sicca syndrome, and 
sustained virological response. Results. There was significant improvement in HQLQ 
domains of physical functioning, physical disability, social functioning, limitations 
and health distress due to hepatitis, and general health. There was significant 
deterioration in domains of positive well-being, health distress, and mental health. 
There was a significant decline prevalence of CWP (26.3% versus 15.3%, 𝑃 = 0 . 0 1 
5 ). Sicca syndrome prevalence fell insignificantly (12.7% versus 11%). SVR was 
associated positively with all HRQOL changes and significantly with CWP remission. 
Conclusions. HCV antivirals significantly improve poor HRQOL scores and CWP. 
Before treatment, both were common, coassociated, and unaccounted for through 
mixed cryoglobulinemia alone. Although a role of the hepatitis C virus in CWP 
cannot be deduced by these results, symptomatic improvement via antiviral treatment 
exists for this subset of patients. 
1. Introduction 
Past clinical understanding confined the burden of chronic hepatitis C infection 
(HCV) to later stages of hepatic impairment. Now it is known that HCV’s 
extrahepatic manifestations (EHMs) and reduced health-related quality of life 
(HRQOL) often develop before hepatic impairment [1]. Diagnostically, this 
understanding helps uncover underlying HCV in people presenting with associated 
EHMs and vice versa. Prognostically, it is unclear whether EHMs independently 
lower HRQOL in HCV patients and whether they respond to antiviral therapy with or 
without a sustained virological response (SVR). Answers to these questions would 
help to determine whether the burden of EHMs in HCV patients merits additional 
management approaches beyond antiviral therapy.  
HRQOL reduction in HCV is multifactorial. Poor baseline HRQOL is partly 
psychosocial in origin, relating to the stigma of illness, a history of illicit drug use for 
a large proportion of patients, and high rates of fatigue, anxiety, and depression [2, 3]. 
Mood-related aspects of HRQOL may even be organically mediated by HCV 
colonization of brain microglia and activation of brain interleukins [4]. However, 
HRQOL is also impaired through somatic symptoms, which may be specific to HCV 
pathophysiology. For example, HCV patients score worse than hepatitis B patients on 
somatic symptoms of the SF-36 questionnaire, and patients unaware of their HCV 
infection still score worse than the general population [2, 5]. Furthermore, most 
evidence points to an improvement in HRQOL as being associated with SVR after 
treatment with pegylated interferon alone or with ribavirin [2, 6–9], which was 
confirmed by a meta-analysis that also suggests that a minimum change of 4.2 points 
on the SF-36 vitality scale is needed for a significant improvement in HRQOL [3]. 
Several trials, however, show improvements in HRQOL independently of SVR, 
raising the hypothesis that viral suppression alone can achieve significant 
physiological changes [6, 8, 10, 11]. 
HCV associated EHMs create somatic symptoms that probably contribute to patients’ 
lower HRQOL scores, although this has not been sufficiently assessed. Arthralgia and 
myalgia are among the common rheumatological symptoms associated with HCV, 
with one study displaying a prevalence of 23% and 15% for each, respectively [12]. 
Less common rheumatological EHMs include arthritis, vasculitis, sicca syndrome, 
Sjögren’s syndrome, and systemic lupus erythematosus [12, 13].  
Mixed cryoglobulinaemia (MC), which has been found in 1–60% of people with 
HCV, describes the presence of IgM immunoglobulins (rarely IgG or IgA) that form 
complexes with monoclonal (type II) or polyclonal (type III) rheumatoid factors (RFs) 
[12]. Types II and III MC are far commoner than simple cryoglobulinaemia (type I) 
that does not include RF complexes and is not associated with HCV. However, 
reported prevalence of MC depends heavily on the accuracy of laboratory techniques 
in cryoprecipitation at low temperatures and measuring cryoglobulin concentrations.  
Deposition of MC immune complexes, alongside poor clearance and reduced 
complement fragments, can result in small-vessel vasculitis and study populations 
with idiopathic MC have high reported incidences for cutaneous, musculoskeletal, and 
renal manifestations. Therefore, secondary MC may play a common role in EHMs as 
5–10% of HCV patients display an overt MC vasculitic triad of weakness, arthralgia, 
and purpura [13, 14]. Multiple tropism of the virus, particularly to lymphocytes, may 
account for many EHMs with or without development of MC [15]. The HCV virus 
seems to facilitate a state of increased autoantibody and cryoglobulin production by 
expanding B cells through the envelope protein E2 interacting with the CD81 receptor 
and increasing B-cell survival by activating the Bcl2 proto-oncogene [13, 16, 17]. A 
similar state may also be achieved by the virus molecular mimicry of host 
autoantigens [17, 18]. As of yet, no factors specific to host background, environment, 
or viral genotype have been associated with the emergence of EHMs [17]. 
Chronic pain in particular has been shown to impair HRQOL in HCV patients [19]. 
However, apart from a specific role for MC in some cases of arthralgia, there is no 
overarching evidence for a pathogenic role of the virus in most presentations of 
chronic pain. For example, histopathological presence of HCV in muscles of myalgia 
sufferers [13, 20] and an increased prevalence of HCV in fibromyalgia patients have 
not been consistently found [21, 22]. 
There have been limited studies on the role of antiviral therapy for EHMs. Antiviral 
therapy has some evidence for improving pain in the context of MC complicated 
HCV. In one study, arthralgia and myalgia improved for approximately half the 
patients, and in those achieving SVR fatigue and MC levels dropped significantly 
[23]. In another study, interferon and ribavirin therapy cleared MC in 37.8% and 
arthralgia in 80% of patients [24]. However, to our knowledge no other studies have 
yet assessed therapeutic effects on EHMs alongside measured HRQOL changes in 
HCV patients.  
2. Methods 
2.1. Aims 
(1)Investigate whether HRQOL improves following antiviral therapy. (2)Investigate 
whether extrahepatic outcomes improve following antiviral therapy. (3)Determine 
whether an association exists between extrahepatic symptoms and HRQOL before and 
after treatment. (4)Investigate whether improvement in HRQOL or extrahepatic 
symptoms is dependent on SVR after treatment.  
2.2. Ethics 
A study protocol for a cross-sectional epidemiological study into the prevalence of 
musculoskeletal symptoms among HCV positive adults in a Brighton cohort was 
proposed and granted ethics approval by the Brighton East Research Ethics 
Committee in January 2006 (reference. 06/Q/1907/134). 
Out of a cohort of 537 HCV patients managed at the Digestive Diseases Unit at the 
Brighton and Sussex University Hospital Trust (BSUH), in the UK, we assessed the 
results of 118 patients who were not coinfected with HIV or HBV and who had 
completed standard antiviral treatment with pegylated interferon-α and ribavirin. 
2.3. Outcomes 
Participants answered the hepatitis quality of life questionnaire (HQLQ) [25] and a 
survey of symptoms affecting the spine, muscles, bones, and joints before treatment 
and six months after finishing treatment. The HQLQ is generically based on SF-36 
health survey but is validated as a hepatitis-specific instrument in the measurement of 
HRQOL [8]. Outcome measures included presence of chronic widespread pain (CWP) 
according to the Manchester criteria (pain in the axial skeleton and at least two 
contralateral body quadrants for at least 3 months), the number of affected joints, pain 
intensity, and interference with daily life as scored on a visual analogue scale (VAS). 
The binary CWP Manchester criteria outcome was preferred over assessments of 
fibromyalgia, as the latter would require validation via physician led examinations 
(self-reports of having a diagnosis of fibromyalgia at baseline were not considered). A 
lack of physical examinations also excluded the presence of vasculitic rashes from our 
assessments. In the context of this study, patients were considered positive for sicca 
syndrome if they reported both mouth and eye sicca symptoms using standardized 
questions into xeropthalmia and xerostomia; a full assessment of Sjögren’s with 
antiRO/SSA or other autoantibodies was not performed.  
2.4. Statistics 
A paired samples 𝑡 -test or Wilcoxon test was used to analyze changes in HRQOL, 
VAS, and number of painful joints from before treatment to 6 months after treatment. 
An independent samples 𝑡 -test or Mann-Whitney 𝑈   test (nonparametric) was used to 
analyze the relationship between HRQOL changes and SVR. A Pearson chi-square 
test was used in the number of patients with CWP, number of patients with pain for 
more than 3 months, or number of patients who agreed with the statement “I ache all 
over.” Exact 𝑃   values of <0.05 in the two-tailed tests were considered significant.  
3. Results 
3.1. Background Information 
See Table 1. Our cohort reflected a relatively young population with a mean age of 46 
and an overwhelming proportion with a history of intravenous drug use—due to 
Brighton having one of the highest prevalence of IVDU in the UK [26]. 
Unemployment was also prevalent at 41%. Furthermore, 18% of patients had 
preexisting arthritis. Although the presence of RF was common (see Table 2), MC 
prevalence was low at only 5.9%, though laboratory techniques and unsatisfactory test 
completion rates should be taken into account.  
Table 1: Background information. 
 
Background variable % ( 𝑛 ) 
 
Age   
 Mean = 46   
Gender   
 Male  59 (69) 
 Female  41 (48) 
Ethnicity   
 White British 79 (90) 
 White Irish 3 (4) 
 White other 12 (14) 
 Other  6 (6) 
In employment 59 (68) 
Transmission mode   
 Intravenous drugs 77.8 (49) 
 Blood transfusion 3.2 (2) 
 Homosexual sex 6.3 (4) 
 Heterosexual sex 1.6 (1) 
 Other 8 (7) 
 Missing (55) 
Genotype   
 1 36.5 (19) 
 2 3.8 (2) 
 3 26.9 (14) 
 2, 3 30.8 (16) 
 4 1.9 (1) 
 Missing  (66) 
SVR   
 Achieved  67 (76) 
 Not achieved  33 (38) 
 No record (4) 
Arthritis   
 Osteoarthritis 5 (6) 
 Rheumatoid 5 (6) 
 Unknown 5 (6) 
 Other 2.5 (3) 
Positive for cryoglobulins 5.9 (7) 
Inflammatory bowel disease 5.9 (7) 
 
 
Table 2: Background serology. 
 
Assay  
Abnormal 
result  
N (total 
found) 
Normal reference 
range  
Value taken as abnormal 
result  
 
Rheumatoid factor  48 (74) <15 IU/mL  >14 IU/mL 
ANA  5 (76) Nil  >1 : 160  
ENA 4 (65) Nil + 
Mixed 
cryoglobulinemia  
7 (82)  Nil  +  
C3 low 4 (81) 0.75–1.65 g/L  <0.75 g/L  
C4 low 14 (80)  0.14–0.54 g/L  <0.14 g/L  
 
 
 
3.2. HRQOL Outcomes 
There was a statistically significant improvement in scores in the following 6 out of 
the 12 domains of the HQLQ: physical functioning, physical disability, social 
functioning, limitations due to hepatitis, health distress due to hepatitis, and general 
health (see Table 3 and Figure 1). There was a statistically significant deterioration in 
3 of the domains (positive well-being, health distress, and mental health), and there 
was no significant change in the rest of the domains (body pain, role emotional, and 
vitality).  
Table 3: HQLQ scores before and after treatment. 
 
HQLQ domain  
Mean score 
Significance of 
change 
Before 
treatment 
6 months after 
treatment 
P value 
 
Physical functioning 76.3 80.2 0.024 
Role physical 60.2 73.1 0.002 
Body pain 60.6 66.3 0.055 
General health 50.9 59.1 >0.001 
Vitality 46.1 43.9 0.233 
Social functioning 62.4 70.4 0.009 
Role emotional 63.8 69.3 0.350 
Mental health 63.3 59.5 0.048 
Health distress 63.8 52.8 0.008 
Positive well-being 68.1 51.6 >0.001 
Hepatitis-specific functional 
limitations 
58.6 69.3 >0.001 
Hepatitis-specific distress 17.2 46.3 >0.001 
 
 
 
Figure 1: HQLQ scores before and after treatment. 
 
 
3.3. Rheumatological Outcomes 
There were a high baseline prevalence of chronic pain symptoms and statistically 
significant declines after treatment in the number of patients with CWP (11% 
reduction, 𝑃 = 0 . 0 1 5 ), number of patients with pain for more than 3 months (11% 
reduction, 𝑃 = 0 . 0 4 1 ), or number of patients who agreed with the statement “I ache 
all over” (10.1%, 𝑃 = 0 . 0 2 9 ) (see Table 4).  
 
 
Table 4: EHMs before and after treatment. 
 
Extrahepatic symptom 
Prevalence/mean score 
Significance of 
change  
(P value) 
Before 
treatment 
6 months after 
treatment 
 
CWP 26.3% 15.3% 0.015 
Sicca syndrome 12.7% 11% 0.804 
Average pain intensity in past 
month (0–10) 
3.5 3.03 0.135 
Interference with daily activities in 
past month (0–10) 
2.91 2.67 0.48 
Number of painful joints in past 
month 
2.59 2.24 0.306 
Pain for more than 3 months 64.4% 53.4% 0.041 
“I ache all over” 23.7% 13.6% 0.029 
 
 
 
Having CWP before treatment was significantly associated with worse pretreatment 
pain levels (5.7/10 versus 2.7/10, 𝑃 > 0 . 0 0 1 ) and their interference with daily life 
as reported on VAS (5.0/10 versus 2.1/10, 𝑃 > 0 . 0 0 1 ), though the overall VAS pain 
scores and the average number of painful joints did not fall significantly after 
treatment. Having CWP before treatment was also negatively associated with all 
HQLQ domains (significantly in all except vitality and health distress and hepatitis-
specific distress), except for positive well-being where people with CWP scored 
significantly higher (75/100 versus 66/100, 𝑃 = 0 . 0 2 3 ) (see Table 5).  
 
Table 5: Variables associated with pretreatment CWP.  
 
  
CWP before 
treatment  
No CWP before 
treatment 
Statistical 
significance (P 
value) 
 
No. of painful joints 5.19 1.67 >0.001 
VAS pain rating (mean)  5.7/10 2.7/10 >0.001 
VAS interference rating 
(mean) 
5.0/10 2.1/10 >0.001 
HQLQ domain       
 Physical functioning 66.8 79.7 0.025 
 Role physical 46.5 65.1 0.025 
 Body pain 38.5 68.6 >0.001 
 General health 40.6 54.6 0.002 
 Vitality 47.1 45.8 NS (0.553) 
 Social functioning 52.4 65.9 0.028 
 Role emotional 46.2 70.1 0.005 
 Mental health 57.2 65.5 0.035 
 Health distress 56.1 66.5 NS (0.182) 
 Positive well-being 74.8 65.7 0.023 
 Hepatitis-specific 
functional limitations 
48.5 62.2 0.014 
 Hepatitis-specific 
distress 
26.3 14.0 NS (0.064) 
  
A remission of CWP after treatment was significantly associated with improvements 
in the HQLQ domain of body pain (15.4 improvement in CWP remission versus 11.8 
if it stays the same and 14.8 reduction if CWP develops, 𝑃 = 0 . 0 2 4 ), physical 
function ( 𝑃 = 0 . 0 4 3 ), and nearly role emotional ( 𝑃 = 0 . 0 5 2 ) (see Figure 2). In 
contrast to pretreatment CWP, having CWP after treatment was only significantly 
associated with a worse role physical and body pain HQLQ score (  = 0 . 0 0 8 , 𝑃 < 0 
. 0 0 1 ). 
 
Figure 2: Pretreatment HQLQ scores in people with CWP versus no CWP. 
 
There were a small number of patients who matched the study’s criteria for sicca 
syndrome, and the decline after treatment was not significant (12.7% versus 11%, 𝑃 = 
0 . 8 0 4 ).  
3.4. Associations with SVR 
After treatment 67% of patients achieved SVR. There were positive nonsignificant 
associations between SVR and changes in all HQLQ scores and significant positive 
associations between SVR and changes in CWP (  = 0 . 0 3 8 ) (see Figure 3). 
However, achieving SVR was not associated with the minor regression in sicca 
symptoms. 
 
 
Figure 3: CWP progression versus SVR. 
 
4. Discussion 
4.1. Quality of Life 
Patients in this study showed significant improvement in 6 of the 12 domains of 
HQLQ following treatment, which on the whole improved the total score. However, 
these improvements did not include an increase of more than 4.2 points on the vitality 
scale, which has been defined by Spiegel et al. as the minimally clinically important 
difference in HRQOL [3]. Therefore, to argue that in this case antiviral therapy has 
had a positive effect on HRQOL is dependent on the weighting given to different 
domains.  
In keeping with previous studies, HRQOL improvement was seen in the domains 
relating to physical health [2, 6, 7]. Given the significant improvement in domains 
relating to general health, disease limitations, social functioning, and hepatitis-related 
distress, the deterioration in domains relating to mental well-being and positive well-
being distress suggests a complex range of effects with antiviral treatment. This may 
be an exacerbation of a high baseline incidence of anxiety and depressive symptoms, 
which are commonly reported among HCV-infected patients [11, 27]. These baseline 
symptoms may be related to a patient’s distress at being diagnosed with a chronic and 
serious illness [28], a history of illicit drug use [29], or a direct effect of the virus [30]. 
The exacerbation of these symptoms, on the other hand, may be caused by antiviral 
treatment itself, as interferon alpha is known to cause depression [27]. Our results 
support the hypothesis that initial impairments in physical domains are more likely to 
be virus related than impairments in domains of mental health given that the former 
domains improved following treatment while the latter did not [1, 31].  
4.2. Rheumatological Symptoms 
Our results reflect the direction of previous findings that fewer patients experience 
myalgia and arthralgia following treatment [23, 24, 32]. Interestingly, however, while 
patients with CWP, 3-month pain and “I ache all over” reported that pain levels all fell 
significantly, the average VAS pain intensity and impact levels, bodily pain aspects of 
the HQLQ, and the number of painful joints were all low and changed little with 
treatment. This demonstrates that extrahepatic pain manifestations in HCV patients 
pool together in a subset of patients and are unaltered by treatment in the majority of 
cases.  
An analysis comparing patients with and without CWP before treatment revealed 
baseline HQLQ scores to be significantly worse in 9 domains in those with CWP, 
though whether this was cause or effect is not ascertainable here. The discrepancy of a 
greater positive well-being in patients with baseline CWP represents a psychological 
anomaly as mental health and other psychological domains were significantly worse 
in this subset. CWP remission after treatment was also significantly associated with an 
improved body pain and physical function score, which changed little otherwise for 
the whole cohort. This shows that having CWP before treatment is significantly 
associated with a worse HRQOL and that the bodily pain aspect may be particularly 
responsive to treatment in this subset, which has not been illustrated in the literature 
before. The clinical implications for this lie in better recognition of this subset of 
patients in order to discuss the potential effects of treatment for them specifically and 
in using appropriate additional management strategies such as analgesia or exercise.  
If the observed trends in pain reflect the effects of a viral immunomodulatory process 
affecting a subset of patients, one would expect more patients to also undergo 
remission of sicca syndrome. A lack of response to treatment may be due to unknown 
factors and an already underwhelming sicca prevalence in the cohort relative to other 
studies. [33]. However, a more evident response would be expected because sicca 
syndrome has an established viral pathogenesis where HCV exocrine gland tropism is 
strongly associated with lymphocytic infiltration, sometimes in combination with 
rheumatoid factor and autoantibodies and resultant xerostomia and xerophthalmia 
[34]. Arthralgia on the other hand is more known to be associated with HCV through 
a mechanism of elevated autoantibodies and MC that promotes tissue injury, a 
biomarker which was rare in our cohort [35]. Thus, our observed improvements in 
pain scores may also be due to unmeasured nonvirological changes, such as nutritional 
status improvements, reduced alcoholic consumption, and subsequent improvements 
in vitamin D levels that are associated with nonspecific musculoskeletal pain [36]. 
4.3. SVR Discussion 
Data from a meta-analysis of HRQOL studies in HCV patients has suggested that 
SVR is associated with improved HRQOL. In this study, there was a general trend in 
that direction without statistical significance, which reflects the power of the sample 
size. Our results suggest that antiviral therapy can improve HRQOL and pain scores in 
the absence of SVR, which may be due to a placebo response, which this study did not 
control for, or due to the immunomodulatory effects of antiviral therapy, which have 
not been fully described yet. For example, interferon has been found to have 
antiproliferative effects on MC and has been used on MC even before link with HCV 
was found. Furthermore, it has been suggested that this effectiveness may be 
irrespective of interferon’s antiviral properties [37]. Conversely, other studies have 
shown that MC and subsequent vasculitic symptoms can persist despite SVR [38], 
which supports the hypothesis of there being both memory (virus-dependent) and 
naïve (virus-independent) autoimmune B cell expansion after HCV infection [24]. 
5. Limitations 
The main drawback of this study is the lack of a matched control group not 
undergoing antiviral treatment, due to there being only a minority of such patients, of 
whom many have concurrent psychiatric illness, IVDU, and alcoholism. Furthermore, 
concomitant use of vitamin D supplementation, analgesia, and anti-inflammatories 
during questionnaire completion was not controlled for. Due to the small proportion of 
patients with the extrahepatic symptoms in this study, a larger sample may be 
necessary to improve the power of measuring the effects of treatment and SVR. 
Therefore, larger study participation with controls and longer followup are needed to 
validate the study’s results. 
6. Conclusions 
Antiviral therapy with pegylated interferon-α and ribavirin can significantly improve 
physical and functional aspects of HRQOL as well as rheumatological CWP 
symptoms in HCV patients, despite no changes in vitality and deterioration in mental 
health and positive well-being. In our cohort, CWP prevalence is high, demonstrably 
related to HRQOL, and unaccounted for through cryoglobulinaemia alone. A role for 
the virus in CWP is purely speculative on the basis of these results, and other potential 
causes such as vitamin D deficiency were not measured. Of relevance to clinical 
practice, however, are the study’s observed CWP prevalence and response in HCV 
patients undergoing antiviral treatment. An awareness of this finding may prompt 
earlier diagnosis and investigation of CWP in HCV patients and warrant chronic pain 
relief as an additional indication for antiviral treatment besides existing benefits on 
hepatitis and HRQOL. Additional management strategies such as graded exercise and 
analgesia should be discussed in this subset of chronic pain sufferers for whom 
antivirals are deemed inappropriate.  
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MC: Mixed cryoglobulinaemia 
SS: Sicca syndrome. 
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